In re: Iovate Health Sciences International Inc., et al.

CourtUnited States Bankruptcy Court, S.D. New York
DecidedMay 12, 2026
Docket25-11958
StatusUnknown

This text of In re: Iovate Health Sciences International Inc., et al. (In re: Iovate Health Sciences International Inc., et al.) is published on Counsel Stack Legal Research, covering United States Bankruptcy Court, S.D. New York primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
In re: Iovate Health Sciences International Inc., et al., (N.Y. 2026).

Opinion

UNITED STATES BANKRUPTCY COURT SOUTHERN DISTRICT OF NEW YORK -----------------------------------------------------------------------x In re: FOR PUBLICATION

IOVATE HEALTH SCIENCES Chapter 15 INTERNATIONAL INC., et al., Case No. 25-11958 (MG)

Debtors in a Foreign Proceeding -----------------------------------------------------------------------x

MEMORANDUM OPINION GRANTING FOREIGN REPRESENTIVE’S MOTION (I) RECOGNIZING AND ENFORCING THE REVERSE VESTING ORDER; (II) APPROVING THE TRANSFER OF THE DEBTORS’ EXCLUDED PROPERTY; AND (III) GRANTING RELATED RELIEF

A P P E A R A N C E S:

PACHULSKI STANG ZIEHL & JONES LLP Counsel to the Foreign Representative 1700 Broadway, 36th Floor New York, New York 10019 By: Steven W. Golden, Esq. Mary F. Caloway, Esq. (admitted pro hac vice)

MARTIN GLENN CHIEF UNITED STATES BANKRUPTCY JUDGE

Pending before the Court is Iovate Health Sciences International’s (“Iovate”), in its capacity as the authorized foreign representative (the “Foreign Representative”), Motion for Entry of an Order: (I) Recognizing and Enforcing the Approval and Reverse Vesting Order; (II) Approving the Transfer of the Debtors’ Excluded Property; and (III) Granting Related Relief (the “Motion,” ECF Doc. # 91). Two declarations are filed in support of the Motion – (1) the Declaration of Noah Goldstein (“Goldstein Decl.,” ECF Doc. # 92) and (2) the Declaration of Michael De Lellis (“De Lellis Decl.,” ECF Doc. # 93). The Motion seeks entry of an order that (a) recognizes and enforces the Ontario Superior Court of Justice’s (the “Canadian Court”) Approval and Reverse Vesting Order (the “Reverse Vesting Order” ECF Doc. # 99 Ex. A) approving the Subscroption Agreement dated April 2, 2026 (the “Subscription Agreement,” Goldstein Decl. Ex. C) between Xiwang Iovate Holdings

Company Limited (“Iovate Holdings”) and 1001542267 Ontario Inc. (the “Purchaser”) and the related transactions contemplated by the Subscription Agreement (the “Transaction”); and approving under sections 363, 1520, and 1521 of the Bankruptcy Code the transfer Iovate, Iovate Health Sciences U.S.A. Inc. (“Iovate US”), and Northern Innovations Holding Corp. (“Northern Innovations” and, together with Iovate and Iovate US, the “Chapter 15 Debtors”) right, title, and interest in and to certain “excluded” United States assets, contracts, and liabilities to a newly- formed corporation (“ResidualCo”) pursuant to the Reverse Vesting Order, as well as related relief. (Motion at 1-2.) I. BACKGROUND A. Case Background

On September 5, 2025, the Chapter 15 Debtors and associated debtors (the “Canadian Debtors”) commenced a proceeding under Canada’s Bankruptcy and Insolvency Act (R.S.C. 1985, c. B-3) (as amended, the “BIA”). (Motion ¶ 3.) Upon the grant of an order from the Canadian Court approving the proceeding and permitting Iovate to act as the Foreign Representative, the Foreign Representative commenced this Chapter 15 case on September 9, 2025. (Id. ¶¶ 4-5.) While initially proceeding under the BIA, the Canadian Debtors soon sought to convert the BIA proceeding into a proceeding under the Canadian Companies’ Creditors Arrangement Act, R.S.C. 1985, c. C-36 (as amended, the “CCAA”). (Id. ¶ 6.) The Canadian Court issued an order on October 31, 2025, granting the Canadian Debtors’ Motion to convert the proceeding under the CCAA (the “CCAA Proceeding”), appointing KSV Restructuring Inc. (“KSV” or the “Monitor”) as the Monitor, and Iovate remained the Foreign Representative. (Id. ¶ 7.) This Court, after initially granting provisional relief to the Chapter 15 Debtors under the BIA

proceeding (ECF Doc. # 20), later recognized the CCAA Proceeding (“CCAA Recognition Order,” ECF Doc. # 86). (Id. ¶ 8.) B. The Sale Process The Canadian Court granted an order approving a sale and investment solicitation process (the “SISP”) to be conducted by the Monitor with assistance of the Canadian Debtors and Origin Merchant partners as sales agent (the “Sales Agent”). (Goldstein Decl. ¶ 4.) The Canadian Court later granted an order giving the Monitor enhanced power to supervise and manage the Canadian Debtors’ business to ensure a fair administration of the CCAA proceeding and SISP. (Id. ¶ 5.) The enhanced powers granted to the Monitor enabled them to exercise any powers that could be properly exercised by a board of debtors of the Canadian Debtors.

The Monitor conducted the SISP in two phases (“Phase 1” and “Phase 2”, respectively). (Id. ¶ 7.) The Monitor, with the assistance of the Sales Agent, determined the following SISP milestones: SISP Commencement November 13, 2025 Court approval of SISP November 28, 2025 Phase 1 Bid Deadline February 4, 2026 Phase 1 Bid Assessment and February 11, 2026 Notification (if any) Phase 2 Qualified Bid Deadline (if March 20, 2026 applicable) Auction (if applicable) March 27, 2026 Selection of Successful Bid April 1, 2026 Approval Order Hearing April 15, 2026 Outside Date June 17, 2026 (Id.) The Monitor received ten (10) letters of intent by the Phase 1 Bid Deadline; from these letters the Sales Agent received four (4) offers with only two (2) in the form as required by the SISP. (Id. ¶¶ 9, 11.) On April 1, 2026, the Monitor and Sales Agent selected the bid submitted by the Purchaser to be implemented pursuant to the Subscription Agreement. (Id. ¶ 12.) The

Monitor determined that the bid from the Purchaser was superior to all other bids submitted. The table below summarizes the principal terms of the Subscription Agreement:1 Parties Xiwang Iovate Holdings Company Limited, as the Company.

1001542267 Ontario Inc., as the Purchaser. Transaction Structure The Transaction is structured as a reverse vesting transaction whereby: • at Closing, the Purchaser will subscribe for and acquire 100 common shares in the capital of the Company (the “Purchased Shares”), free and clear of all Encumbrances (other than Permitted Encumbrances); • the Existing Shares and all related plans, agreements, options, and rights will be terminated and cancelled for no consideration; • the Excluded Assets, Excluded Contracts and Excluded Liabilities (collectively, the “Excluded Property”) will be transferred to and vested in ResidualCo pursuant to the Reverse Vesting Order; and • the Principal Entities (being, the Company, Iovate International, Iovate USA, Northern Innovations and Iovate Australia) Deposit The Purchaser has paid to the Monitor a Deposit representing approximately 10% of the Purchase Price. Retained Assets All assets, properties, Business Intellectual Property, Retained Contracts, undertakings and rights of every kind owned by the Principal Entities as of Closing, as set forth in Schedule 1.1(cccc) to the Subscription Agreement, and not including the Excluded Assets. Excluded Assets Excluded Assets include: • tax records and Books and Records relating to Excluded Liabilities; • Excluded Contracts; • the Closing Payment;

1 Capitalized terms not otherwise defined are intended to have the meanings ascribed to them in the Subscription Agreement. • rights in favor of ResidualCo under the Subscription Agreement; • assets specifically set forth in Schedule 2.2; and • any other assets identified by the Purchaser as Excluded Assets no later than two business days before Closing. Retained Liabilities The following liabilities shall be retained by the Principal Entities: • all Post-Filing Claims; • all Liabilities under the Retained Contracts arising from and after Closing; • Cure Costs; • Tax Liabilities for any period from and after Closing; • demand promissory notes owing by the Company to Xiwang Foodstuffs (Qingdao) Co., Ltd and Xiwang Foodstuffs Co. Ltd. in the aggregate amount of approximately US $49 million; • certain pre-filing accounts payable as determined by the Purchaser; and • any other Liabilities identified by the Purchaser as Retained Liabilities no later than two business days before Closing.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
In re: Iovate Health Sciences International Inc., et al., Counsel Stack Legal Research, https://law.counselstack.com/opinion/in-re-iovate-health-sciences-international-inc-et-al-nysb-2026.